Just Published: "Hungary Pharmaceuticals & Healthcare Report Q4 2015"

Hungary's improving macroeconomic outlook and pledges by the government to raise healthcare expenditure will boost pharmaceutical sales in the coming years. Consumer demand for over-the-counter medicines and greater uptake of generic medicines will be the primary drivers of pharmaceutical sales growth, as uptake of innovative drugs will remain hindered by the pricing sensitivity and budgetary constraints of the OEP national healthcare fund. However, Hungary's attractiveness to multinational drugmakers will remain impeded by onerous regulatory burden, pricing pressures and punitive taxes on pharmaceutical companies.

Headline Expenditure Projections

Full Report Details at
- http://www.fastmr.com/prod/1032895_hungary_pharmaceuticals.aspx?afid=301

Pharmaceuticals: HUF640.21bn (USD2.75bn) in 2014 to HUF652.76bn (USD2.31bn) in 2015; +2.8% in local currency terms and -15.9% in US dollar terms.

Healthcare: HUF2,382bn (USD10.23bn) in 2014 to HUF2,427bn (USD8.60bn) in 2015; +1.9% in local currency terms and -15.9% in US dollar terms.

Risk/Reward Index

Hungary currently ranks fourth out of the 20 regional markets profiled in the Central and Eastern Europe region, with a score of 56.0. While its Risks profile is generally predictable, Hungary's Rewards score has improved considerably due to favourable currency effects and our improving outlook for the country's pharmaceutical market.

Key Trends & Developments

In July 2015, the National Institute of Pharmacy and Nutrition (OGYEI) announced that all drugs containing codeine were to be transferred from the over-the-counter category to prescription-only category.

In July 2015, the Hungarian parliament passed the Act on Primary Healthcare, delegating the responsibility of primary care to municipal governments.

The Hungary Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Hungary Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Hungary pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Hungary, to test other views - a key input for successful budgeting and strategic business planning in the Hungarian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Hungarian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Hungary.
* Assess the activities, strategy and market position of your competitors

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Nigeria Pharmaceuticals & Healthcare Report Q4 2015
- Kenya Pharmaceuticals & Healthcare Report Q4 2015
- Pakistan Pharmaceuticals & Healthcare Report Q4 2015
- Mexico Pharmaceuticals & Healthcare Report Q4 2015
- Thailand Pharmaceuticals & Healthcare Report Q4 2015